Screening and production of an affibody inhibiting the interaction of the PD1/PD-L1 immune checkpoint

An affibody is a 58 amino acids peptide derived from the Z domain of staphylococcal protein A and generally applied in areas such as imaging diagnosis, clinical therapeutics and biotechnology research. To screen for an affibody targeting the immune checkpoint PD-L1, a combinatorial affibody library was generated in yeast using degenerate overlap PCR primers and In-fusion technology. Z-jl and Z-j2 affibodies targeting the Ig-like V domain of PD-Ll were screened and identified from this combinatorial library using the yeast two hybrid system. The Zji and Z-j2 recombinant affibody proteins were over produced in E.coli and purified. ELISA and GST pull-down assays showed that recombinant Z-jl and Z-j2 affibody proteins bound with high affinity to PD-Ll and inhibited the interaction of PD-1/PD-Ll. Thus, novel affibodies targeting the immune checkpoint PD-1/PD-L1 were identified and produced in this study and have the potential to be used in cancer immunotherapy.